Homepage
Author:
Artios Pharma
Posted Date:
May 26, 2026
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
Artios Pharma
May 26, 2026
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors
Artios Pharma
May 12, 2026
Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution
Artios Pharma
May 4, 2026
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
Artios Pharma
March 2, 2026
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
Artios Pharma
February 23, 2026
Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline
Artios Pharma
February 16, 2026
